Literatur
- 1
Wettengel R, Böhning W, Cegla U. et al .
Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch
obstruktiver Bronchitis und Lungenemphysem.
Med Klin.
1995;
90
3-7
- 2
Pauwels R A, Buist A S, Calverley P MA. et al .
Global strategy for the diagnosis, management, and prevention of chronic obstructive
pulmonary disease.
Am J Respir Crit Care Med.
2001;
163
1256-1276
- 3
ATS Statement .
Standards for the diagnosis and care of patients with chronic obstructive pulmonary
disease.
Am J Respir Crit Care Med.
1995;
152
S77-S120
- 4
Siafakas N M, Vermeire P, Pride N B. et al .
ERS-Consensus statement. Optimal assessment and management of chronic obstructive
pulmonary disease.
Eur Respir J.
1995;
8
1388-1420
- 5
BTS .
Guidelines for the management of chronic obstructive pulmonary disease.
Thorax.
1997;
52 (Suppl 5)
S1-S28
- 6 Canadian Respiratory Review Panel .Guidelines for the treatment of chronic obstructive
pulmonary disease (COPD). Monograph 1998
- 7
Laitinen L, Koskela K. et al .
Chronic bronchitis and chronic obstructive pulmonary disease: Finnish national guidelines
for prevention and treatment 1998 - 2007.
Respir Med.
1999;
93
207-332
- 8
Lorenz W, Ollenschläger G. et al .
Das Leitlinienmanual von AWMF und ÄZQ.
ZaeFQ.
2001;
95 (Suppl. I)
41-43
- 9 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften .Erarbeitung
von Leitlinien für Diagnostik und Therapie. Methodische Empfehlungen. Abrufbar unter:
http://www.uni-duesseldorf.de/WWW/AWMF
- 10
Society for Medical Decision Making .
Committee on standardization of clinical algorithms. Proposals for clinical algorithm
standards.
Med Decis Making.
1992;
12
149-154
- 11
Report of an expert committee .
Definition and diagnosis of pulmonary disease with special reference to chronic bronchitis
and emphysema.
WHO Techn Rep Ser.
1961;
213
14-19
- 12
Ciba guest symposium report .
Terminology, definitions and classifications of chronic pulmonary emphysema and related
conditions.
Thorax.
1959;
14
286-299
- 13 Konietzko N, Fabel H. Weißbuch Lunge 2000. Stuttgart-New York: Thieme
- 14 Statistisches Bundesamt .Statistisches Jahrbuch, Jahrgänge 1968 - 1999. Stuttgart-Mainz:
Kohlhammer
- 15 Murray C JL, Lopez A D. The global burden of disease: A comprehensive assessment
of mortality and disability from diseases. Injuries and risk factors in 1990 and projected
to 2020. Cambridge: Harvard University Press 1996
- 16
Lopez A D, Murray C JL.
The global burden of disease, 1990 - 2020.
Nature Med.
1998;
4
1241-1243
- 17
Rychlik R, Pfeil T, Daniel D. et al .
Zur sozioökonomischen Relevanz akuter Exacerbationen der chronischen Bronchitis in
der Bundesrepublik Deutschland.
Dtsch Med Wschr.
2001;
126
353-359
- 18
Laurell C B, Eriksson S.
The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency.
Scand J Clin Lab Invest.
1963;
15
132-140
- 19 Orie N GM, Sluiter H J, De Vreis K. et al .The host factor in bronchitis. In: Orie
NGM, Sluiter HJ, (eds). Bronchitis, an international symposium. Assen, Netherlands:
Royal Vangorum 1961: 43-59
- 20
Svanes C, Omenaas E, Heuch J M. et al .
Birth characteristics and asthma symptoms in young adults: results from a population-based
cohort study in Norway.
Eur Respir J.
1998;
12
1366-1370
- 21
Todisco T, de Benedictis F M, Iannacci L. et al .
Mild prematurity and respiratory functions.
Eur J Pediatr.
1993;
152
55-58
- 22
Stein C E, Kumaran K, Fall C H. et al .
Relation of fetal growth to adult lung function in South India.
Thorax.
1997;
52
895-899
- 23
Morgan W J.
Maternal smoking and infant lung function: further evidence for an in utero effect.
Am J Respir Crit Care Med.
1998;
158
689-690
- 24 U. S. Surgeon General .The health consequences of smoking: chronic obstructive
pulmonary disease. Washington DC.: U. S. Department of health and human services 1984
Publication No. 84 - 50 205
- 25
Leuenberger P, Schwartz J, Ackermann-Liebrich U. et al .
Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study).
Swiss Study on air pollution and lung diseases in adults. SAPALDIA Team.
Am J Respir Crit Care Med.
1994;
150
1222-1228
- 26
Dayal H H, Khuder S, Sharrar R. et al .
Passive smoking in obstructive respiratory disease in an industrialized urban population.
Environ Res.
1994;
65
161-171
- 27
Holt P G.
Immune and inflammatory function in cigarette smokers.
Thorax.
1987;
42
241-249
- 28
Kauffmann F, Droulet D, Lellouch J. et al .
Twelve years spirometric changes among Paris area workers.
Int J Epidemiol.
1979;
8
201-212
- 29 Niewoehner D E. Anatomic and pathophysiological correlations in COPD In Baum Gl,
Crapo JD, Celli BR, Karlinsky JB, (eds.) Textbook of pulmonary diseases. Philadelphia:
Lippincott-Raven 1998: 823-842
- 30
Chen J C, Mannino M D.
Worldwide epidemiology of chronic obstructive pulmonary disease.
Current Opin Pulmon Med.
1995;
5
93-99
- 31
Behera D, Jindal S K.
Respiratory symptoms in Indian women using domestic cooking fuels.
Chest.
1991;
100
385-388
- 32 Georgopoulos D, Anthonisen N R. Symptoms and signs of COPD. In: Cherniack NS (ed).
Chronic obstructive pulmonary disease. Toronto: Saunders 1991: 357-363
- 33
Taube M D, Lehnigk B, Paasch K. et al .
Factor analysis of changes in dyspnea and lung function parameters after bronchodilatation
in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2000;
162
216-220
- 34
O'Donnell D E, Lam M, Webb K A.
Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic
obstructive pulmonary disease.
Am J Respir Crit Care Med.
1998;
158
1557-1565
- 35
O'Donnell D E, Lam M, Webb K A.
Spirometric correlates for improvement in exercise performance after anticholinergic
therapy in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1999;
160
542-549
- 36
Marin J M, Carrizo S J, Gascon M. et al .
Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance
during the 6-minute-walk test in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
163
1395-1399
- 37
Seemungal T A, Donaldson G C, Bhownik A. et al .
Time course and recovery of exacerbations in patients with chronic obstructive pulmonary
disease.
Am J Respir Crit Care Med.
2000;
161
1608-1613
- 38
Traver G A, Cline M G, Burrows B.
Predictors of mortality in COPD.
Am Rev Respir Dis.
1979;
119
895-902
- 39
Burrows B.
The course and prognosis of different types of chronic airflow limitation in a general
population sample from Arizona: comparison with the Chicago “COPD” series.
Am Rev Respir Dis.
1989;
140
92-94
- 40
Quanjer P H.
Standardised lung function testing. Official statement of the European Respiratory
Society.
Eur Respir J.
1993;
6 (Suppl 16)
5-40
- 41
Tweeddale P W, Alexander F, McHardy G JR.
Short term variability in FEV1 and bronchodilator responsiveness in patients with
obstructive ventilatory defects.
Thorax.
1987;
42
87-90
- 42
Guyatt G H, Townsend M, Nogradi S. et al .
Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in
chronic airflow limitation.
Arch Intern Med.
1988;
148
1949-1952
- 43
Berger R, Smith D.
Effect of an inhaled metaproterenol on exercise performance in patients with stable
“fixed” airway obstruction.
Am Rev Respir Dis.
1988;
138
626-629
- 44
Gross N, Tashkin D, Miller R. et al .
Inhalation by nebulization of albuterol-ipratropium combination (Dey combination)
is superior to either agent alone in the treatment of chronic obstructive pulmonary
disease. Dey Combination Solution Study Group.
Respiration.
1998;
65
354-362
- 45
Guyatt G H, Townsend M, Pugsley S O. et al .
Bronchodilators in chronic air-flow limitation: effects on airway function, exercise
capacity and quality of life.
Am Rev Respir Dis.
1987;
135
1069-1074
- 46
Callahan C M, Cirrus R S, Katz B P.
Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary
disease: a meta-analysis.
Ann Intern Med.
1991;
114
216-223
- 47
American Thoracic Society .
Lung function testing: selection of reference values and interpretation strategies.
Am Rev Respir Dis.
1991;
144
202-218
- 48
Roberts C M, Bugler J R, Melchor R. et al .
Value of pulse oximetry for long-term oxygen therapy requirement.
Eur Respir J.
1993;
6
559-562
- 49
Hughes J MB, Pride N B.
In defense of the carbon monoxide transfer coefficent Kco(TL/VA).
Eur Respir J.
2001;
17
168-174
- 50
McLean A, Warren P M, Gilooly M. et al .
Microscopic and macroscopic measurement of emphysema: relation to carbon monoxide
transfer.
Thorax.
1992;
47
14-19
- 51
Gevenois P A, de Vuyst P, de Maertelaer V. et al .
Comparison of computed density and microscopic morphometry in pulmonary emphysema.
Am J Respir Crit Care Med.
1996;
154
187-192
- 52
Gould G A, Redpath A T, Ryan M. et al .
Lung CT density correlates with measurements of airflow limitation and the diffusing
capacity.
Eur Respir J.
1991;
4
141-146
- 53 Worth H, Breuer H-W M, Dorow P. et al .Deutsche Gesellschaft für Pneumologie. Empfehlungen
zur Durchführung und Bewertung von Belastungsuntersuchungen in der Pneumologie. 52
1998: 225-231
- 54
Thurlbeck W M, Simon G.
Radiographic appearance of the chest in emphysemas.
Am J Roentgenol.
1978;
130
429-440
- 55
Morgan M DL, Denison D M, Stricklund B.
Value of computed tomography for selecting patients with bullous emphysema.
Thorax.
1986;
41
855-862
- 56
Lehtonen J, Sutinen S, Ikaheimo M. et al .
Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified
at autopsy.
Chest.
1988;
93
839-842
- 57
Niedermeier J, Barner A, Borst M. et al .
Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Anwendung der Echokardiographie
in der pneumologischen Diagnostik.
Pneumologie.
1998;
52
519-521
- 58
Worth H, Adam D, Handrick W. et al .
Prophylaxe und Therapie von bronchopulmonalen Infektionen. Empfehlungen der Deutschen
Atemwegsliga.
Pneumologie.
1998;
52
232-237
- 59
O'Donnell D E, Forkert L, Webb K A.
Evaluation of bronchodilator responses in patients with “irreversible” emphysema.
Eur Respir J.
2001;
18
914-920
- 60
Begin P, Grassino A.
Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary
disease.
Am Rev Respir Dis.
1991;
143
901-903
- 61
Baldi S, Miniati M, Bellina C R. et al .
Relationship between extent of pulmonary emphysema by high-resolution computed tomography
and lung elastic recoil in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
169
585-589
- 62
Wolkove N, Dacezman E, Colacone A. et al .
The relationship between pulmonary function and dyspnoea in obstructive lung disease.
Chest.
1989;
96
1247-1251
- 63
Connolly M C, Crowley J J, Charan N B. et al .
Reduced subjective awareness of bronchoconstriction by metacholine in elderly asthmatic
and normal subjects as measured on a simple awareness scale.
Thorax.
1992;
47
410-413
- 64
Wilson D H, Wakefield M A, Steven I D. et al .
“Sick of smoking” evaluation of a targeted minimal smoking cessation intervention
in general practice.
Med J Aust.
1990;
152
518-521
- 65
Britton J, Knox A.
Helping people to stop smoking: the new smoking cessation guidelines.
Thorax.
1999;
54
1-2
- 66
Kottke T E, Ballista R N, de Friese G H. et al .
Attributes of successful smoking cessation interventions in medical practise. A meta-analysis
of 39 controlled trials.
JAMA.
1988;
259
2883-2889
- 67
Ockene J K, Kristeller J, Goldberg R. et al .
Increasing the efficacy of physician delivered smoking interventions: a randomized
controlled clinical trial.
J Gen Intern Med.
1991;
6
1-9
- 68 Fiore M C, Bailey W C, Cohen S J. Smoking cessation: information for specialists.
U.S. department of health and human services. Public health service. Agency for health
care policy and research and centers for disease control and prevention. Rockville:
M.D. AHCPR 1996 Publication No. 96 - 0694
- 69
The tobacco use and dependence clinical practice guideline panel, staff and consortium
repesentatives .
A clinical practice guideline for treating tobacco use and dependence.
JAMA.
2000;
83
3244-3254
- 70 American Medical Association .Guidelines for the diagnosis and treatment of nicotine
dependence. How to help patients stop smoking. Washington D.C.: American Medical Association
1994
- 71 Glynn T J, Manley M W. How to help your patients stop smoking. A national cancer
institute manual for physicians. Bethesda M.D. U.S. Department of health and human
service, public health service. National institutes of health. National Cancer Institute
NIH Publication 90 - 3064 1990
- 72
Anthonisen N R, Connett J E, Kiley J P. et al .
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator
on the rate of decline of FEV1: The Lung Health Study.
JAMA.
1994;
272
1497-1505
- 73 Arzneimittelkommission der Deutschen Ärzteschaft .Empfehlungen zur Therapie der
Tabakabhängigkeit. Köln: AVP-Reihe 2001
- 74
Jorenby R E, Leischow S J, Nides M A. et al .
A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking
cessation.
N Engl J Med.
1999;
340
685-691
- 75
Tashkin D P, Kanner R J, Buist S. et al .
Smoking cessation in patients with chronic obstructive pulmonary disease: a double
blind, placebo-controlled randomised trial.
Lancet.
2001;
357
1571-1575
- 76 WHO .Tobacco free initiative: Policies for public Health. www.who//int/toh/world
nottobacco 99
- 77 Fiore M C, Bailey W C, Cohen S J. et al .Treating tobacco use as dispendence: A
clinical practical guideline. A public health service report. Rockville, M.D.: US
Dept Health and Human Services 2000
- 78 Schwartz J L. Review and evalution of smoking cessation methods: United States
and Canada, 1978 - 1985. Bethesda, M.D.: National Institute of Health 1987 NIH publication
87 - 2940
- 79
Fiore M C, Smith S S, Jorenby D E. et al .
The effectiveness of the nicotine patch for smoking cessation. A meta-analysis.
JAMA.
1994;
271
1940-1947
- 80
Sachs D E, Benowitz N L.
Individual medical treatment for tobacco dependence [editorial; comment].
Eur Respir J.
1996;
9
629-631
- 81
Nichol K, Margolis L, Wourenma J. et al .
The efficacy and cost effectiveness of vaccination against influenza among elderley
persons living in the community.
N Engl J Med.
1994;
331
778-784
- 82
Hak E, van Essen G A, Buskens E. et al .
Is immunising all patients with chronic lung disease in the community against influenza
cost effective? Evidence from a general based clinical prospective cohort study in
Utrecht. The Netherlands.
J Epidemiol Community Health.
1998;
52
120-125
- 83
Simberkoff M S, Cross A P, Al-Ibrahim M. et al .
Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration
Cooperative Study.
N Engl J Med.
1986;
315
1318-1327
- 84
Williams J HJ, Moser K M.
Pneumococcal vaccine and patients with chronic lung disease.
Ann Intern Med.
1986;
104
106-109
- 85
Christenson B, Lundbergh P, Hedlund J. et al .
Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines
in adults aged 65 years or older: a prospective study.
Lancet.
2001;
357
1008-1011
- 86
Davis A L, Aranda P, Schiffman G. et al .
Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic
obstructive pulmonary disease. A pilot study.
Chest.
1994;
92
204-212
- 87
Schaberg T.
Pneumokokkenschutzimpfung.
Pneumologie.
2001;
55
543-545
- 88 Ständige Impfkommission am Robert Koch-Institut (STIKO) .Epidemiologisches Bulletin
des RKI. 28 2001: 203-218
- 89
Pauwels R A, Lofdahl C G, Laitinen L A. et al .
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive
pulmonary disease who continue smoking.
N Engl J Med.
1999;
340
1948-1953
- 90
Vestbo J, Sorensen T, Langer P. et al .
Longterm effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary
disease: a randomised controlled trial.
Lancet.
1999;
355
1819-1823
- 91
Burge P S, Calverley M A, Jones P W. et al .
Randomised, placebo-controlled study of fluticasone proprionate in patients with moderate
to severe chronic obstructive pulmonary disease; the Isolde trial.
Br Med J.
2000;
320
1297-1303
- 92
The Lung Health Study Research Group .
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive
pulmonary disease.
N Engl J Med.
2000;
343
1902-1909
- 93
Van Schayck C P, Dompeling E, van Heerwaarden C LA. et al .
Bronchodilator treatment in modern asthma or chronic bronchitis. Continuous or on
demand. A randomised controlled study.
BMJ.
1991;
303
1426-1431
- 94
Voshaar T, App E M, Berdel D. et al .
Empfehlungen für die Auswahl von Inhalationssystemen für die Medikamentenverabreichung.
Pneumologie.
2001;
55
579-586
- 95
Nisar M, Earis J E, Pearson M G. et al .
Acute bronchodilator trials in chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1992;
146
555-559
- 96
Ulrik C S.
Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive
pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover
study.
Thorax.
1995;
50
750-754
- 97
Grove A, Lipworth B J, Reid P. et al .
Effects of regular salmeterol on lung function and exercise capacity in patients with
chronic obstructive airways disease.
Thorax.
1996;
51
689-693
- 98
Boyd G, Mirice A H, Pounsford J G. et al .
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease
(COPD).
Eur Respir J.
1997;
10
815-821
- 99
Maesen B LP, Wedermann C JJ, Duarkens V AM. et al .
Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary
disease.
Eur Respir J.
1999;
13
1103-1108
- 100
Jones P W, Bosh T K.
Quality of life changes in COPD patients treated with salmeterol.
Am J Respir Crit Care Med.
1997;
155
1283-1289
- 101
Cazzola M, Imperatore F, Salzillo A. et al .
Cardiac effects of formoterol and salmeterol in patients suffering from COPD with
preexisting cardiac arrhythmia.
Chest.
1998;
114
411-415
- 102
Karpel J P, Pesin J, Greenberg D. et al .
A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute
exazerbations of COPD.
Chest.
1990;
98
835-839
- 103
Patrick D M, Dales R E, Stark R M. et al .
Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium
to usual therapy.
Chest.
1990;
98
295-297
- 104
Braun S R, Mc Kenzie W N, Copeland C. et al .
A comparison of the effect of ipratropium and albuterol in the treatment of chronic
airways disease.
Arch Intern Med.
1989;
149
544-547
- 105
Tashkin D P, Ashutosh K, Bleeker E R. et al .
Comparison of the anticholinergic bronchodilator ipratropiumbromide with metaproterenol
in chronic obstructive pulmonary disease: a multicenter study.
Am J Med.
1986;
81 (Suppl. 5a)
1411-1419
- 106
COMBIVENT Inhalation Aerosol Study Group .
In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol
is more effective than either agent alone: an 85-day multicenter trial.
Chest.
1994;
105
1411-1419
- 107
Rennard S I.
Extended bronchodilator treatment in chronich obstructive pulmonary disease.
Eur Respir Rev.
1996;
6
282-286
- 108
Barnes P J.
The pharmacological properties of tiotropium.
Chest.
2000;
117
63-66
- 109
Calverley P MA.
The future of tiotropium.
Chest.
2000;
117
67-69
- 110
Casaburi R, Mahler D A, Jones P W. et al .
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary
disease.
Eur Respir J.
2002;
19
217-224
- 111
Vincken W, von Noord J A, Greefhorst A P. et al .
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
Eur Respir J.
2002;
19
209-216
- 112
Murciano D, Auclair M-A, Pariente R. et al .
A randomized controlled trial of theophylline in patients with severe chronic obstructive
pulmonary disease.
N Eng J Med.
1989;
320
1512-1525
- 113
Mc Kay S E, Howie C A, Thomson A H. et al .
Value of theophylline treatment in patients handicapped by chronic obstructive pulmonary
disease.
Thorax.
1993;
48
227-232
- 114
Mulloy E, Mc Nicholas W T.
Theophylline improves gas exchange during rest, exercise and sleep in severe chronic
obstructive pulmonary disease.
Am Rev Respir Dis.
1993;
148
1030-1036
- 115
Evans W W.
Plasma theophylline concentrations, six minute walking distances and breathlessness
in patients with chronic airflow obstruction.
BMJ.
1984;
289
1649-1651
- 116
Cooper C B, Davidson A C, Cameron I R.
Aminophylline, respiratory muscle strength and exercise tolerance in chronic obstructive
airway disease.
Clin Respir Physiol.
1987;
23
15-22
- 117
Murciano D, Aubier M, Lecolguic Y. et al .
The effects of theophylline on diaphragmatic strength an exercise tolerance in patients
with chronic obstructive pulmonary disease.
N Engl J Med.
1984;
322
349-353
- 118
Williamson B H, Milligan C, Griffiths K. et al .
An assessment of major and minor side effects of theophylline.
Aust NZ J Med.
1988;
19
539
- 119
Kirsten D, Wegner R E, Jörres R A. et al .
Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease.
Chest.
1993;
104
1101-1107
- 120
The COMBIVENT Inhalation Solution Study Group .
Routine nebulized ipratropium and albuterol together are better than either alone
in COPD.
Chest.
1997;
112
1514-1521
- 121
Taylor D R, Buick B, Kinney C. et al .
The efficacy of orally administered theophylline, inhaled salbutamol and a combination
of the two as chronic therapy in the management of chronic bronchitis with reversible
airflow obstruction.
Am J Respir Dis.
1985;
131
747-751
- 122
Van Noord J A, de Munck D R, Bantje T A. et al .
Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the
additive effect of ipratropium.
Eur Respir J.
2000;
15
878-885
- 123
D'Urzo A D, de Salvo M C, Ramirez-Rivera A. et al .
In patients with COPD, treatment with a combination of formoterol and ipratropium
is more effective than a combination of salbutamol and ipratropium.
Chest.
2001;
119
1347-1356
- 124
O'Driscoll B R, Kay E A, Taylor R J. et al .
A long-term prospective assessment of home nebulizer treatment.
Respir Med.
1992;
S6
317-325
- 125
Washkin D P, Bleecker E, Braun S. et al .
Results of a multicenter study of nebulized inhalant bronchodilator solutions.
Am J Med.
1996;
100
62-69
- 126
Senderovitz T, Vestbo J, Frandsen J. et al .
Steroid reversibility test followed by inhaled budesonide or placebo in outpatients
with stable chronic obstructive pulmonary disease. The Danish Society or Respiratory
Medicine.
Respir Med.
1999;
93
715-718
- 127
Rice K L, Rubins J B, Lebhahn F. et al .
Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized
trial.
Am J Respir Crit Care Med.
2000;
162
174-178
- 128
Decramer M, Lacquet L M, Fagard R. et al .
Corticosteroids contribute to muscle weakness in chronic airflow obstruction.
Am J Respir Crit Care Med.
1994;
150
11-16
- 129
Decramer M, Stas K J.
Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic
obstructive pulmonary disease or asthma.
Am J Respir Dis.
1992;
146
800-802
- 130
Schols A MWJ, Wesseling G, Keser A DM. et al .
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids.
Eur Respir J.
2001;
17
337-342
- 131
Grassi C. and the multicenter Study Group .
Longterm oral acetylcysteine in chronic bronchitis. A double blind controlled study.
Eur J Respir Dis.
1980;
61 (Suppl. 111)
93-108
- 132
Boman G, Bäcker U, Larsson S. et al .
Oral acetylcysteine reduces exacerbation rate in chronic bronchitis. Report of a trial
organized by the Swedish Society for Pulmonary Diseases.
Eur J Respir Dis.
1983;
64
405-415
- 133
Jackson M, Barnes J, Cooksey P.
Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: A
double-blind placebo-controlled study.
J Int Med Res.
1984;
12
198-205
- 134
Mc Gavin C R. and the British Thoracic Society Research Committee .
Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and
severe airway obstruction.
Thorax.
1985;
40
832-835
- 135
Meister R.
Langzeittherapie mit Acetylcystein Retard-Tabletten bei Patienten mit chronischer
Bronchitis. Eine doppelblinde-placebokontrollierte Studie.
Forum Prakt Allg Arzt.
1986;
25
18-22
- 136
Parr G D, Huitson A.
Oral fabrol (oral N-acetylcysteine) in chronic bronchitis.
Br J Dis Chest.
1987;
81
341-348
- 137
Rasmussen J B, Glennow C.
Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release
tablets in patients with chronic bronchitis.
Eur Respir J.
1988;
1
351-355
- 138
Hansen N CG, Skriver A, Brorsen-Ries L. et al .
Orally administered N-acetylcysteine may improve general well-being in patients with
mild chronic bronchitis.
Respir Med.
1994;
88
531-535
- 139
Pela R, Calcagni A M, Subiaco S. et al .
N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe
COPD.
Respiration.
1999;
66
495-500
- 140
Grandjean E M, Berthet P, Ruffmann R. et al .
Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A
metaanalysis of published double blind, placebo-controlled clinical trials.
Clin Therapeutics.
2000;
22
209-221
- 141
Stey C, Steuer J, Bachmann S. et al .
The effect of oral N-acetylcysteine in chronic bronchitis - a quantitative systematic
review.
Eur Respir J.
1999;
14 (Suppl. 30)
381S
- 142
Poole P J, Black P N.
Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease.
BMJ.
2001;
322
1-6
- 143
Olivieri D, Zavattini G, Tomasini G. et al .
Ambroxol for the prevention of chronic bronchitis exazerbations: long term multicenter
trial.
Respiration.
1987;
51 (Suppl 1)
42-51
- 144
Collet J P, Shapiro S, Ernst P. et al .
Effect of an immunostimulating agent on acute exacerbations and hospitalizations in
COPD patients.
Am J Respir Crit Care Med.
1997;
156
1719-1724
- 145
Anthonisen N R.
Editoral. OM-85BV for COPD.
Am J Respir Crit Care Med.
1997;
156
1713-1714
- 146
Irwin R S, Boulet L P, Cloutier M M. et al .
Managing cough as a defense mechanism and as a symptom: a consensus panel report of
the American College of Chest Physicans.
Chest.
1998;
114
133S-181S
- 147
Bardsley P A, Howard P, DeBacker W. et al .
Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive
airways disease.
Eur Respir J.
1991;
4
308-310
- 148
Watanabe S, Kanner R E, Cutillo A G. et al .
Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive
pulmonary disease.
Am J Respir Dis.
1989;
140
1269-1273
- 149 Winkelmann B R, Kullmer T H, Kneissl D G. et al .Low-dose almitrine bismesylate
in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest
105: 1383-1391
- 150
Eiser N, Denman W T, West C. et al .
Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the “pink puffer”
syndrome.
Eur Respir J.
1991;
4
926-931
- 151
Young I H, Daviskas E, Keena V A.
Effect of low dose nebulised morphine on exercise endurance in patients with chronic
lung disease.
Thorax.
1989;
44
387-390
- 152
Rice K L, Kronenberg R S, Hedemark L L. et al .
Effects of chronic administration of codeine and promethazine on breathlessness and
exercise tolerance in patients with chronic airflow obstruction.
Br J Dis Chest.
1987;
81
287-292
- 153
Woodcock A A, Gross E R, Gellert A A. et al .
Effects of dihydrocodeine, alcohol and caffeine on breathlessness and exercise tolerance
in patients with chronic obstructive lung disease and normal blood gases.
N Engl J Med.
1981;
305
1611-1616
- 154
Poole P J, Veale A G, Black P N.
The effect of sustained release morphine on breathlessness and quality of life in
severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1998;
157
1877-1880
- 155
Schönhofer B, Suchi S, Haidl P. et al .
Eine Epidemiologie zum Stellenwert von oral appliziertem Morphium als Therapieform
des schwergradigen Lungenemphysems vom Pink-Puffer-Typ.
Med Klin.
2001;
96
325-330
- 156
Alpha-1-Antitrypsin Deficiency Registry Group .
Survival and FEV1 decline in individuals with severe deficiency of a1-antitrypsin.
Am J Respir Crit Care Med.
1998;
158
49-59
- 157
Seersholm N, Kokjensen A.
Clinical features and prognosis of life time non-smokers with severe α1-antitrypsin
deficiency.
Thorax.
1998;
53
265-268
- 158
Wencker M, Banik N, Buhl R.
Long-term treatment of α1-antitrypsin deficiency related pulmonary emphysema with
human α1-antitrypsin.
Eur Respir J.
1998;
11
428-433
- 159
Incalci R A, Caradonna P, Ranieri P. et al .
Correlates of osteoporosis in chronic obstructive pulmonary disease.
Respir Med.
2000;
94
1079-1084
- 160
American College of Rheumatology ad hoc Committee on glucocorticoid-induced osteoporosis
.
Recommendations for the prevention and treatment of glucocortocoid-induced osteoporosis.
Arthritis Rheumatism.
2001;
44
1496-1503
- 161
Engelken M PKJ, Schols A MWJ, Baker W C. et al .
Nutritional depletion in relation to respiratory and peripheral muscle function in
outpatients with COPD.
Eur Respir J.
1994;
7
1793-1797
- 162
Schols A MWJ, Soeters P B, Dingemans A MC. et al .
Prevalence and characteristics of nutritional depletion in patients with stable COPD
eligible for pulmonary rehabilitation.
Am Rev Respir Dis.
1993;
147
1187-1196
- 163
Wilson D O, Rogers R M, Wright E C. et al .
Body weight in chronic obstructive pulmonary disease. The National Institutes of Health
intermittend positive-pressure breathing trial.
Am Rev Respir Dis.
1989;
139
1435-1438
- 164
Wouters E FM, Schols A MWJ.
Nutritional depletion in COPD.
Eur Respir Rev.
1997;
7
60-65
- 165
Fitting J W.
Nutritional support in chronic obstructive lung disease.
Thorax.
1992;
47
141-143
- 166
Hunter A BN, Carey M A, Lorch H W.
The nutritional status of patients with chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1985;
132
1347-1365
- 167
Gray-Donald K, Gibbone L, Shapiro S H. et al .
Nutritional status and mortality in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1996;
153
961-966
- 168
Baarends E M, Schols A MWJ, Mostert R. et al .
Peak exercise in relation to tissue depletion in patients with chronic obstructive
pulmonary disease.
Eur Respir J.
1997;
10
2807-2813
- 169
Shoup R, Dalshy G, Warner G. et al .
Body composition and health related quality of life in patients with chronic obstructive
airways disease.
Eur Respir J.
1997;
10
1576-1580
- 170
Schols A MWJ, Slangen J, Volorris A. et al .
Weigth loss is a reversible factor in the prognosis of COPD.
Am J Respir Crit Care Med.
1998;
157
1791-1797
- 171
Efthimiou J, Fleming J, Gomes C. et al .
The effect of supplementary oral nutrition in poorly nourished patients with chronic
obstructive pulmonary disease.
Am Rev Respir Dis.
1988;
137
1075-1082
- 172 Rogers R M, Donahue M, Constantino J. Physiologic effects of oral supplemental
feeding in malnourished patients with chronic obstructive pulmonary disease patients. Am
Rev Respir Dis 145: 1511-1597
- 173
Whittaker J S, Buckley C F, Road J D.
The effects of re-feeding on peripheral and respiratory muscle function in malnourished
chronic obstructive pulmonary disease patients.
Am Rev Respir Dis.
1990;
142
283-288
- 174
Ries A L, Kaplan R M, Limberg T M. et al .
Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients
with chronic obstructive pulmonary disease.
Ann Intern Med.
1995;
122
823-832
- 175
Toshima M C, Kaplan R M, Ries A L.
Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease.
Short term effects on exercise endurance and health status.
H Psychol.
1999;
9
237-252
- 176
Gallefoss F, Bakke P S.
How does patient education and self management among asthmatics and patients with
chronic obstructive pulmonary disease affect medication?.
Am J Respir Crit Care Med.
1999;
160
2000-2005
- 177
Lacasse Y, Guyatt G H, Goldstein R S.
The components of a rehabilitation program. A systematic review.
Chest.
1997;
111
1077-1088
- 178
Dhein Y, Birkenmaier A, Otte B. et al .
Evaluation of a structured education programme (AFBE) for patients with mild to moderate
COPD under outpatient conditions.
Am J Respir Crit Care Med.
2002;
165
A420
- 179
Murray J F.
The ketch-up bottle method.
N Engl J Med.
1979;
300
1155-1157
- 180
Anthonisen P, Ries P, Sogaard-Andersen T.
The value of lung physiotherapy in the treatment of acute exacerbations in chronic
bronchitis.
Acta Med Scand.
1964;
145
715-719
- 181
Graham W, Bradley G A.
Efficacy of chest physiotherapy and intermittent positive-pressure breathing in the
resolution of pneumonia.
N Eng J Med.
1978;
299
624-627
- 182
King M, Philips D M, Gron D. et al .
Enhanced tracheal mucus clearance with high frequency chest wall percussion.
Am Rev Respir Dis.
1983;
128
511-515
- 183
Pryer J A.
Physiotherapy for airway clearance in adults.
Eur Respir J.
1999;
14
1418-1424
- 184
Cegla U H, Petzow A.
Physiotherapie mit dem VRP1 bei chronisch obstruktiven Atemwegserkrankungen - Ergebnisse
einer multizentrischen Vergleichsstudie.
Pneumologie.
1993;
47
636-639
- 185
App E M, Wunderlich M O, Lohse P. et al .
Oszillierende Physiotherapie bei Bronchialerkrankungen - rheologischer und antientzündlicher
Effekt.
Pneumologie.
1999;
53
1-12
- 186
Cegla U H, Bautz M, Fröde G. et al .
Physiotherapie bei Patienten mit COPD und tracheobronchialer Instabilität - Vergleich
zweier oszillierender PEP-Systeme (RC-Cornet, VRP1-Destin).
Pneumologie.
1997;
51
129-136
- 187
ACCP/AAC/VPR Pulmonary Rehabilitation Guidelines Panel .
Pulmonary Rehabilitation.
Chest.
1997;
112
1363-1395
- 188
American Thoracic Society .
Pulmonary Rehabilitation.
Am J Respir Crit Care Med.
1999;
159
1666-1682
- 189
Lacasse Y, Wong E, Guyatt G H. et al .
Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease.
Lancet.
1996;
348
1115-1119
- 190
Hass A, Cardon H.
Rehabilitation in chronic obstructive pulmonary disease: 5 year study of 252 patients.
Med Clin North Am.
1969;
53
593-606
- 191
Sahn S A, Nett L M, Petty T L.
Ten-year follow-up of a comprehensive rehabilitation programme for severe COPD.
Chest.
1980;
77
311-314
- 192
Wedzicha J A, Bestall J C, Garrod R. et al .
Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive
pulmonary disease patients, stratified with the MRC dyspnoea scale.
Eur Respir J.
1998;
12
363-369
- 193
Young P, Dewse M, Fergusson W. et al .
Respiratory rehabilitation in chronic obstructive pulmonary disease: predictors of
non-adherence.
Eur Respir J.
1999;
13
867-872
- 194
Bergmann K, Fischer C J, Schmitz M. et al .
Die stationäre Rehabilitation für Erwachsene. Zielsetzung - Diagnostik und therapeutische
Standards - Forschungsbedarf.
Pneumologie.
1997;
51
523-532
- 195
Szczepanski R, Taube K, Junggeburth J. et al .
Ambulante wohnortnahe pneumologische Prävention und Rehabilitation bei obstruktiven
Atemwegserkrankungen - Stand, Perspektive und Forschungsbedarf.
Pneumologie.
1998;
52
476-482
- 196
Goldstein R S, Gort E H, Stubbing D. et al .
Randomized controlled trial of respiratory rehabilitation.
Lancet.
1994;
344
1394-1397
- 197
Wijkstra P J, van Atena R, Kraan J. et al .
Quality of life in patients with chronic obstructive pulmonary disease improve after
rehabilitation at home.
Eur Respir J.
1994;
7
307-311
- 198
McGavin C R, Gapta S P, Lloyd E L. et al .
Physical rehabilitation for the chronic bronchitis. Results of a controlled trial
of exercises in the home.
Thorax.
1977;
32
307-311
- 199
Griffiths T L, Burr M L, Campbell I A. et al .
Results at 1 year of out-patient multidisciplinary pulmonary rehabilitation.
Lancet.
2000;
355
362-368
- 200
Worth H, Meyer A, Folgering H. et al .
Empfehlungen der Deutschen Atemwegsliga zum Sport und körperlichen Training bei Patienten
mit obstruktiven Atemwegserkrankungen.
Pneumologie.
2000;
54
61-67
- 201
Bernhard S, Whittom F, Leblanc P. et al .
Aerobic and strength training in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1999;
159
896-901
- 202
Belman M J, Botnick W C, Nathan S D. et al .
Ventilatory load characteristics during ventilatory muscle training.
Am J Respir Crit Care Med.
1994;
149
925-929
- 203
Foglio K, Bianchi L, Bruletti G. et al .
Long-term effectiveness of pulmonary rehabilitation in patients with chronic airways
obstruction.
Eur Respir J.
1999;
13
125-132
- 204
Young P, Dewse M, Ferguson W. et al .
Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable
to a hospital-based respiratory rehabilitation programme.
Aus NZ J Med.
1999;
29
59-65
- 205
Carter R, Blevins W, Stocks J. et al .
Cost and quality issues related to the management of COPD.
Sem Resp Med.
1999;
20
199-212
- 206
Magnussen H, Goeckenjan G, Köhler D. et al .
Leitlinien zur Sauerstoff-Langzeit-Therapie.
Pneumologie.
2001;
55
454-464
- 207
Report of the Medical Research Council Working Party .
Long-term domiciliary oxygen in chronic cor pulmonale complicating chronic bronchitis
and emphysema.
Lancet.
1981;
1
681-685
- 208
Nocturnal oxygen therapy trial group .
Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary
disease.
Ann Intern Med.
1980;
93
191-198
- 209
Weitzenblum E, Sautegeau A, Ehrhart M. et al .
Long-term oxygen therapy can reverse the progression of pulmonary hypertension in
patients with chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1985;
131
493-498
- 210
Leach R M, Davidson A C, Chinn S. et al .
Portable liquid oxygen and exercise ability in severe respiratory disability.
Thorax.
1992;
47
78-789
- 211
Tarpy S P, Celli B R.
Long-term oxygen therapy.
N Engl J Med.
1995;
333
710-714
- 212
Pelletier Fleury N, Laone J L, Fleury B. et al .
The cost of treating COPD patients with long-term oxygen therapy in a French population.
Chest.
1996;
110
411-416
- 213
Heaney L G, McAllister D, MacMahon J.
Cost minimisation analysis of provision of oxygen at home: are the drug tariff guidelines
cost effective?.
BMJ.
1999;
319
19-23
- 214
Donahoe M, Rogers R M.
Nutritional assessment and support in chronic pulmonary disease.
Clin Chest Med.
1990;
11
487-504
- 215
Köhler D, Criée C-P, Raschke F.
Leitlinien zur häuslichen Sauerstoff- und Heimbeatmungstherapie.
Pneumologie.
1996;
50
927-931
- 216
Simmonds A K, Elliot M W.
Outcome of domiciliary nasal intermittent positive pressure ventilation in restrictive
and obstructive disorders.
Thorax.
1995;
50
604-609
- 217
Meecham Jones D J, Paul E A, Jones P W. et al .
Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone
in hypercapnic COPD.
Am J Respir Crit Care Med.
1995;
152
538-544
- 218
Consensus Conference .
Clinical indications for noninvasive positive pressure ventilation in chronic respiratory
failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. A consensus
conference report.
Chest.
1999;
116
521-534
- 219
Mehran R J, Deslauriers J.
Indications for surgery and patient work-up for bullectomie.
Chest Surg Clin N Am.
1995;
5
717-734
- 220
Hughes J A, Hutchison D M, MacArthur D CS. et al .
Long-term changes in lung function after surgical treatment of bullos emphysema in
smokers and exsmokers.
Thorax.
1986;
39
140
- 221
Brantigan O C, Kress M B, Müller E A.
A surgical approach to pulmonary emphysema.
Dis Chest.
1961;
39
485-501
- 222
Cooper J D, Trulock E P, Triantafillou A N. et al .
Bilateral pneumonectomy (volume reduction) for chronic obstructive pulmonary disease.
J Thorac Cardiovasc Surg.
1995;
109
106-119
- 223
Geddes D, Davies M, Koyama H. et al .
Effect of lung volume reduction surgery in patients with severe emphysema.
N Engl J Med.
2000;
343
239-245
- 224
Benditt J O, Albert R K.
Surgical options for patients with advanced emphysema.
Clin Chest Med.
1997;
18
577-593
- 225
A National Emphysema Treatment Trial Research Group .
Patients at high risk of death after lung-volume-reduction surgery.
N Engl J Med.
2001;
345
1075-1083
- 226
Cassina P C, Teschler H, Konietzko N. et al .
Two-year results after lung volume reduction surgery in alpha-1-antitrypsin deficiency
versus smoker's emphysema.
Eur Respir J.
1998;
12
1028-1032
- 227
Thurnheer R, Engel H, Weder W. et al .
Role of lung perfusion scintigraphy in relation to chest computed tomography and pulmonary
function in the evaluation of candidates for lung volume reduction surgery.
Am J Respir Crit Care Med.
1999;
159
301-310
- 228
Brenner M, McKenna R JJ, Gelb A F. et al .
Rate of FEV1 change following lung volume reduction surgery.
Chest.
1998;
113
652-659
- 229
McKenna R J, Brenner M, Fischel R J. et al .
Should lung volume reduction for emphysema be unilateral or bilateral?.
J Thorac Cardivasc Surg.
1996;
112
1331-1339
- 230
Sciurba F C.
Early and long-term functional outcomes following lung volume reduction surgery.
Clin Chest Med.
1997;
18
259-276
- 231
Stamatis G, Teschler H, Fechner S. et al .
Bilaterale Lungenvolumenreduktion bei Patienten mit schwerem Lungenemphysem.
Pneumologie.
1996;
50
448-452
- 232
Wisser W, Deviatko E, Simon N. et al .
Lung transplantation following lung volume reduction surgery.
J Heart Lung Transplant.
2000;
19
480-487
- 233
Theodore J, Lewiston N.
Lung transplantation comes of age.
N Engl J Med.
1990;
322
772-774
- 234
Trulock E P.
Lung transplantation.
Am J Respir Crit Care Med.
1997;
155
789-818
- 235 Division of transplantation Bo .1995 Annual report of the US scientific registry
for transplant recipients and the organ procurement and transplantation network. Transplant
data: 1988 - 1994. Health Resources and Services Administration. US Department of
Health and Human services 1995
- 236
Hosenpud J D, Novick R J, Bennett L E. et al .
The registry of the international society for heart and lung transplantation: twelfth
official report.
J Heart Lung Transplant.
1996;
15
655-674
- 237
Hosenpud J D, Bennett L E, Keck B M. et al .
Effects of diagnosis on survival benefit of lung transplantation for end-stage lung
disease.
Lancet.
1998;
3
24-27
- 238
Niedermeier J, Bewig B, Bickhardt T. et al .
Lungen- und Herz- und Lungentransplantation. Leitlinien zur Indikationsstellung und
Präoperativen Diagnostik.
Pneumologie.
2001;
55
396-400
- 239
Trulok E P.
Lung transplantation for COPD.
Chest.
1998;
113
269-276
- 240
Ramsey S D, Patrick D L, Albert R K. et al .
The cost-effectiveness of lung transplantation: a pilot study.
Chest.
1995;
108
1594-1601
- 241
Molken M P, van Doorslaer E K, Rutten F F.
Economic appraisal of asthma and COPD care: a literature review 1980 - 1991.
Soc Sci Med.
1992;
35
161-175
- 242
Kroshus T J, Bolmann III R M, Kshettry V R.
Unilateral volume reduction after single-lung transplantation for emphysema.
Ann Thorac Surg.
1996;
62
363-368
- 243
Anderson M B, Kriett J M, Kapelanski D P. et al .
Volume reduction surgery in the native lung after single lung transplantation for
emphysema.
J Heart Lung Transplant.
1997;
16
752-757
- 244
Anthonisen N R, Manfreda J, Warren C P. et al .
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med.
1987;
106
196-204
- 245
Regueiro C R, Hamel M B, Davis R B. et al .
A comparison of generalist and pulmonologist care for patients hospitalized with severe
chronic obstructive pulmonary disease: resource intensity, hospital costs and survival.
Am J Med.
1998;
105
366-372
- 246
Gibson P G, Wlodarczyk J H, Wilson A J. et al .
Severe exacerbations of chronic obstructive airways disease: health resource use in
general practice and hospital.
J Qual Clin Pract.
1998;
18
125-133
- 247
Mushlin A I, Black E A, Connolly C A. et al .
The necessary length of hospital stay for chronic pulmonary disease.
JAMA.
1991;
266
80-83
- 248
Connors A F, Dawson N V, Thomas C. et al .
Outcomes following acute exacerbation of severe chronic obstructive lung disease.
The SUPPORT investigators.
Am J Respir Crit Care Med.
1996;
154
959-967
- 249
Kong G K, Belman M J, Weingarten S.
Reducing length of stay for patients hospitalized with exacerbation of COPD by using
a practice guideline.
Chest.
1997;
111
89-94
- 250
Fuso L, Incalzi R A, Pistelli R. et al .
Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive
pulmonary disease.
Am J Med.
1995;
98
272-277
- 251
Seneff M G, Wagner D P, Wagner R P. et al .
Hospital and 1-year survival of patients admitted to intensive care units with acute
exacerbation of chronic obstructive pulmonary disease.
JAMA.
1995;
274
1852-1857
- 252
MacFarlane J T, Colville A, Macfarlane R M. et al .
Prospective study of aetiology and outcome of adult lower-respiratory-tract infections
in the community.
Lancet.
1993;
341
511-514
- 253
Stockley R A, O'Brien C, Pye A. et al .
Relationship of sputum color to nature and outpatient management of acute exacerbations
of COPD.
Chest.
2000;
117
1638-1645
- 254
Seemungal T R, Harpen-Owen R, Bhownik A. et al .
Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and
stable chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
164
1618-1623
- 255
Anderson H R, Spix C, Medina S. et al .
Air pollution and daily admissions for chronic obstructive pulmonary disease in 6
European cities: results from the APHEA project.
Eur Respir J.
1997;
10
1064-1071
- 256
Emerman C L, Connors A F, Lukens T W. et al .
Relationship between arterial blood gases and spirometry in acute exacerbations of
chronic obstructive pulmonary disease.
Ann Emerg Med.
1989;
18
523-527
- 257
Emerman C L, Effron D, Lukens T W.
Spirometric criteria for hospital admission of patients with acute exacerbation of
COPD.
Chest.
1991;
99
595-599
- 258
Emerman C L, Lukes T W, Effron D.
Physician estimation of FEV1 in acute exacerbation of COPD.
Chest.
1994;
105
1709-1712
- 259
Emerman C L, Cydulka R K.
Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation
of chronic obstructive pulmonary disease [see comments].
Ann Emerg Med.
1996;
27
159-163
- 260
Rice K L, Leatherman J W, Duane P G. et al .
Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A
controlled trial.
Ann Intern Med.
1987;
107
305-309
- 261
Barbera J A, Reyes A, Roca J. et al .
Effect of intravenously administered aminophylline on ventilation/perfusion inequality
during recovery from exacerbations of chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1992;
145
1328-1333
- 262
Mahon J L, Laupacis A, Hodder R V. et al .
Theophylline for irreversible chronic airflow limitation: a randomized study comparing
n of 1 trials to standard practice.
Chest.
1999;
115
38-48
- 263
Loberes P, Ramis L, Montserrat J M. et al .
Effect of three different bronchodilators during an exacerbation of chronic obstructive
pulmonary disease.
Eur Respir J.
1988;
1
536-539
- 264
Emerman C L, Connors A F, Lukens T W. et al .
Theophylline concentrations in patients with acute exacerbation of COPD [see comments].
Am J Emerg Med.
1990;
8
289-292
- 265
Eller J, Ede A, Schaberg T. et al .
Infective exacerbations of chronic bronchitis.
Chest.
1998;
113
1542-1548
- 266
Vogel F, Worth H, Adam D. et al .
Rationale Therapie bakterieller Atemwegsinfektionen. Empfehlungen einer Expertengruppe
der Paul-Ehrlich-Gesellschaft für Chemotherapie und der Deutschen Atemwegsliga.
Chemother J.
2000;
9
3-23
- 267
Thompson W H, Nielson C P, Carvalho P. et al .
Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation.
Am J Respir Crit Care Med.
1996;
154
407-412
- 268
Davies L, Angus R M, Calverley P M.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic
obstructive pulmonary disease: a prospective randomised controlled trial.
Lancet.
1999;
354
456-460
- 269
Niewoehner D E, Erbland M L, Deupree R H. et al .
Effect of systemic glucocorticoids on exacxerbations of chronic obstructive pulmonary
disease.
N Engl J Med.
1999;
340
1941-1947
- 270
Bach P B, Brown C, Gelfand S E. et al .
Management of acute exacerbations of chronic obstructive pulmonary disease: a summary
and appraisal of published evidence.
Ann Intern Med.
2001;
134
600-620
- 271
Rossi A, Gottfried S B, Zocci L. et al .
Respiratory mechanics in mechanically ventilated patients with respiratory failure.
J Appl Physiol.
1985;
58
1849-1858
- 272
Georgopoulos D, Rossi A, Moxham J.
Ventilatory support in chronic obstructive pulmonary disease.
Eur Respir Mon.
1998;
7
189-208
- 273
Bott J, Carroll M P, Conway J H. et al .
Randomized controlled trial of nasal ventilation in acute ventilatory failure due
to chronic obstructive airways disease.
Lancet.
1993;
341
1555-1557
- 274
Brochard L, Mancebo J, Wysocki M. et al .
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.
N Engl J Med.
1995;
33
817-822
- 275
Kramer N, Meyer T J, Meharg J. et al .
Randomized, prospective trial of noninvasive positive pressure ventilation in acute
respiratory failure.
Am J Respir Crit Care Med.
1995;
151
1799-1806
- 276
Barbé F, Togores B, Rubi M. et al .
Noninvasive ventilatory support does not facilitate recovery from acute respiratory
failure in chronic obstructive pulmonary disease.
Eur Respir J.
1996;
9
1240-1245
- 277
Plant P K, Owen J L, Elliott M W.
Early use of non-invasive ventilation (NIV) for acute exacerbations of COPD on general
respiratory wards: a multicenter randomized controlled trial.
Lancet.
2000;
355
1931-1935
- 278
Nava S, Ambrosino N, Clini E. et al .
Noninvasive mechanical ventilation in the weaning of patients with respiratory failure
due to chronic obstructive pulmonary disease. A randomized, controlled trial.
Ann Intern Med.
1998;
128
721-728
- 279
Stoller J K, Lange P A.
Inpatient management of chronic obstructive pulmonary disease.
Respir Care Clin N Am.
1998;
4
425-438
- 280
Peach H, Pathy M S.
Follow-up study of disability among elderly patients discharged from hospital with
exacerbations of chronic bronchitis.
Thorax.
1981;
36
585-589
- 281
Friedman M, Serby C W, Menjoge S S. et al .
Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared
with ipratropium alone and albuterol alone in COPD.
Chest.
1999;
115
635-641
- 282
Mahler D A, Donohue J F, Barbee R A. et al .
Efficacy of salmeterol xinafoate in the treatment of COPD.
Chest.
1999;
115
957-965
- 283 Morgan W KG, Reger R B. Chronic airflow limitation and occupation. In: Cherniack
NS (Hrsg.): Chronic obstructive pulmonary disease Philadelphia: Saunders 1991
- 284
Nowak D.
Berufsbedingte obstruktive Atemwegserkrankung (BK4301 und 4302) gutachterliche Anmerkungen
zum Krankheitsbegriff und zur MdE.
Arbeitsmed Sozialmed Umweltmed.
2000;
35
164-167
- 285 Morfeld P, Piekarski C. Chronische Bronchitis und Emphysem als Berufskrankheit
der Steinkohlenbergleute. Schriftenreihe Zentralblatt für Arbeitsmedizin, Haefer 1998
- 286 Nowak D. Informationen zur neuen Berufskrankheit 4111: „Chronische obstruktive
Bronchitis oder Emphysem von Bergleuten unter Tage im Steinkohlenbergbau bei Nachweis
der Einwirkung einer kumulativen Feinstaubdosis von in der Regel 100 [(mg/m3) × Jahre]”. Pneumologie
1996: 652-654
- 287 Kroidl R F, Nowak D, Seysen U. Bewertung und Begutachtung in der Pneumologie. Thieme
1999
- 288 Bundesministerium für Arbeit und Sozialordnung .Anhaltspunkte für die ärztliche
Gutachtertätigkeit im sozialen Entschädigungsrecht und nach dem Schwerbehindertengesetz.
Köllen,. 1996
Prof. Dr. med. H. Worth
Medizinische Klinik I · Klinikum Fürth
Jakob-Henle-Str. 1
90766 Fürth
eMail: med1@klinikum-fuerth.de
